Cut-off levels of CYFRA21-1 to differentiate between metastatic and non-metastatic NSCLC

Lung Cancer

Volumn 48, Issue 1, 2005, Pages 151-152

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^a   Ohtsuka, Morio ^a   Sekizawa, Kiyohisa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADENOCARCINOMA; BONE SCINTISCANNING; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEDICAL INFORMATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR DIFFERENTIATION;

EID: 15044339026     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.10.001     Document Type: Editorial

References (5)

1. B. Wieskopf, C. Demangeat, A. Purohit, R. Strenger, P. Gries, and H. Kreisman Cyfa21-1 as a biologic marker of non-small cell lung cancer Chest 108 1995 163 169
2. R. Lai, H. Hsu, J.Y. Lu, L.P. Ger, and N.S. Lai CYFRA21-1 enzyme-linked immunosorbent assay Chest 109 1996 995 1000
3. Y. Sugama, S. Kitamura, T. Kawai, A. Ohkubo, S. Hasegawa, and T. Kuriyama Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment Jpn J Cancer Res 85 1994 1178 1184
4. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
5. J.A. McNeil, E. Keeler, and S.J. Adelstein Primer on certain elements of decision making N Engl J Med 293 1975 211 215